RxDoctor Payments Data

Christine Won, MD

Internal Medicine · Pasadena, CANPI 1750350252

Payments from drug & device makers

$1,497in general payments, 2019–2025

Across 51 payments — averaging $29.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$324
  • Biohaven Pharmaceutical Holding Company Ltd.$226
  • AbbVie$186
  • Amgen$184
  • E.r. Squibb & Sons, L.L.C.$126
  • Lilly USA, LLC$123
  • plus $328 from 12 others

What the payments were for

  • Food & beverage$1,497100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,497 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$10,127
Medicare patients
48
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin32$31,181
FarxigaDapagliflozin Propanediol16$26,260
EliquisApixaban34$19,480
JanuviaSitagliptin Phosphate11$17,929
MyrbetriqMirabegron12$6,178
LivaloPitavastatin Calcium13$5,760
JentaduetoLinagliptin/Metformin Hcl11$5,675
ElmironPentosan Polysulfate Sodium11$3,411
Rosuvastatin Calcium92$2,042
PaxlovidNirmatrelvir/Ritonavir14$1,429
Ezetimibe29$1,285
Quetiapine Fumarate30$983
Tamsulosin Hcl27$758
Losartan Potassium34$718
SynthroidLevothyroxine Sodium25$666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$22$26,26016 claims
PfizerEliquis, Paxlovid$25$20,90948 claims
MerckJanuvia$23$17,92911 claims
Astellas Pharma US IncMyrbetriq$25$6,17812 claims
Kowa Pharmaceuticals America, Inc.Livalo$25$5,76013 claims
AbbVieSynthroid$186$66625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →